Literature DB >> 19940498

Effects of growth hormone treatment in juvenile idiopathic arthritis: bone and body composition.

S Bechtold1, R Dalla Pozza, H P Schwarz, D Simon.   

Abstract

BACKGROUND: Inflammation and glucocorticoid therapy are major factors influencing growth and bone maturation in patients with juvenile idiopathic arthritis (JIA). In addition to alterations in total bone mineral density and bone geometry, longitudinal data confirm that the main contributors to errant bone maturation in patients with JIA are reductions in muscle mass and force. Growth hormone (GH) therapy, which has shown efficacy in controlling disease, may also positively influence body composition. For several years, GH therapy has been used to treat growth retardation in patients with JIA receiving glucocorticoids. GH therapy normalizes growth velocity, increases height, bone mineral density and bone mass and changes bone geometry. Despite ongoing glucocorticoid therapy, muscle mass and bone size substantially increase with GH therapy. Increased bone size suggests improved bone stability, which may reduce fracture risk. Along with the increase in muscle mass, patients experience stabilized or slightly decreased fat mass during GH therapy.
CONCLUSIONS: All these effects suggest an anabolic effect of GH therapy on bone and body composition. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19940498     DOI: 10.1159/000229766

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  4 in total

1.  Increased rat neonatal activity influences adult cytokine levels and relative muscle mass.

Authors:  Bryce Buchowicz; Tiffany Yu; Dwight M Nance; Frank P Zaldivar; Dan M Cooper; Gregory R Adams
Journal:  Pediatr Res       Date:  2010-11       Impact factor: 3.756

2.  Effects of growth hormone treatment on growth plate, bone, and mineral metabolism of young rats with uremia induced by adenine.

Authors:  Débora Claramunt; Helena Gil-Peña; Rocío Fuente; Enrique García-López; Olaya Hernández Frías; Flor A Ordoñez; Julián Rodríguez-Suárez; Fernando Santos
Journal:  Pediatr Res       Date:  2017-04-26       Impact factor: 3.756

3.  Suppressor of cytokine signaling 2 (Socs2) deletion protects bone health of mice with DSS-induced inflammatory bowel disease.

Authors:  Ross Dobie; Vicky E MacRae; Chloe Pass; Elspeth M Milne; S Faisal Ahmed; Colin Farquharson
Journal:  Dis Model Mech       Date:  2018-01-17       Impact factor: 5.758

4.  Growth Hormone: Therapeutic Possibilities-An Overview.

Authors:  Steve Harvey; Carlos G Martinez-Moreno
Journal:  Int J Mol Sci       Date:  2018-07-11       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.